Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. TIL are a patient’s own T cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. The company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered TIL. The company is led by world-class cell therapy experts and backed by premier global institutional investors. Instil is located in the greater Los Angeles area with additional manufacturing and research facilities in Manchester, UK. 


Biotechnology

Education

Instil Bio

Bronson Crouch

Carol Castaneda

Jennifer Montoya

Artur Burgiel

Steve Dinnogen

Craig Kessler

T. David Chonzi

Sharon McGonagle

Film Sarah Turnbull Fcipd Fitol (Goodfellow)

Sandeep Laumas (Steve)

Robert Bob Hawkins

Mark Dudley

Sandeep Laumas

The Research and Development team at Instil Bio focuses on advancing the company's cell therapy products from conceptualization through clinical trials. This multidisciplinary team employs expertise in process sciences, analytical sciences, cell therapy research, and computational immunology to optimize the manufacturing, scalability, and efficacy of tumor infiltrating lymphocytes (TIL) therapies. Their collaborative efforts drive innovation in developing and refining next-generation engineered TILs to enhance their therapeutic potential for treating solid tumor cancers.

Research and Development

Board & Executive Committee

Finance Team

Research and Development

About

Team members

Other teams at Instil Bio

Board & Executive Committee

Finance Team